These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 140180)

  • 61. Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease.
    Podolsky S; Leopold NA
    Gerontology; 1977; 23(1):55-63. PubMed ID: 136379
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Stimulation of growth hormone secretion by desimipramin and chlorimipramin in man.
    Laakmann G; Schumacher G; Benkert O
    J Clin Endocrinol Metab; 1977 May; 44(5):1010-3. PubMed ID: 870511
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Growth hormone abnormalities in Huntington's chorea: effect of L-dopa administration.
    Podolsky S; Leopold NA
    J Clin Endocrinol Metab; 1974 Jul; 39(1):36-9. PubMed ID: 4276011
    [No Abstract]   [Full Text] [Related]  

  • 64. [Fatty acid patterns and glucose tolerance in Huntington's chorea (author's transl)].
    Schubotz R; Hausmann L; Kaffarnik H; Zehner J; Oepen H
    Res Exp Med (Berl); 1976 Jul; 167(3):203-15. PubMed ID: 136033
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Plasma amino acid levels in Huntington's chorea.
    Watt JA; Cunningham WL
    Br J Psychiatry; 1978 Apr; 132():394-7. PubMed ID: 147718
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Altered growth hormone release in Huntington's chorea.
    Keogh HJ; Johnson RH; Nanda RN; Sulaiman WR
    J Neurol Neurosurg Psychiatry; 1976 Mar; 39(3):244-8. PubMed ID: 132511
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Circadian rhythmicity of prolactin secretion in Huntington's chorea.
    Polleri A; Savoldi F; Muratorio A; Masturzo P; Murialdo G; Martignoni E; Nappi G; Iudice A; Murri L
    Life Sci; 1980 May; 26(19):1609-17. PubMed ID: 6446012
    [No Abstract]   [Full Text] [Related]  

  • 68. Neuroendocrine function in Huntington's disease: dopaminergic regulation of prolactin release.
    Caine E; Kartzinel R; Ebert M; Carter AC
    Life Sci; 1978 Mar; 22(10):911-8. PubMed ID: 147978
    [No Abstract]   [Full Text] [Related]  

  • 69. Endocrine functions in Huntington's disease. A two-and-a-half years follow-up study.
    Kremer HP; Roos RA; Frölich M; Radder JK; Nieuwenhuijzen Kruseman AC; Van der Velde A; Buruma OJ
    J Neurol Sci; 1989 May; 90(3):335-44. PubMed ID: 2525607
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The cerebrospinal fluid choline levels in patients with Huntington's chorea. Negative effect of haloperidol treatment.
    Consolo S; Ladinsky H; Bianchi S; Caraceni T
    Arch Psychiatr Nervenkr (1970); 1977 May; 223(3):265-70. PubMed ID: 142461
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Brain immunoreactive gonadotropin-releasing hormone in Huntington's chorea and in non-choreic subjects.
    Bird ED; Chiappa SA; Fink G
    Nature; 1976 Apr; 260(5551):536-8. PubMed ID: 131252
    [No Abstract]   [Full Text] [Related]  

  • 72. Magnesium metabolism in Huntington's chorea.
    Jones JE; Desper PC; Fink EB
    Metabolism; 1965 Jul; 14(7):813-8. PubMed ID: 25286470
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of DA agonist in Huntington disease hyperkinesia.
    Caraceni TA; Girotti F; Giovannini P; Pederzoli M; Parati EA
    Ital J Neurol Sci; 1980 Jun; 1(3):155-61. PubMed ID: 6210644
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Uptake of dopamine and 5-hydroxytryptamine by platelets from patients with Huntington's chorea.
    McLean DR; Nihei T
    Lancet; 1977 Jan; 1(8005):249-50. PubMed ID: 64769
    [No Abstract]   [Full Text] [Related]  

  • 75. Dopamine uptake capacity of platelets from people at risk for Huntington's chorea.
    McLean DR; Nihei T
    Can J Neurol Sci; 1981 May; 8(2):167-8. PubMed ID: 6457680
    [No Abstract]   [Full Text] [Related]  

  • 76. [Amino acids in the blood in Huntington's chorea].
    Oepen H; Oepen I
    Humangenetik; 1965; 1(3):299-302. PubMed ID: 4223837
    [No Abstract]   [Full Text] [Related]  

  • 77. A 24-Hour Study of the Hypothalamo-Pituitary Axes in Huntington's Disease.
    Kalliolia E; Silajdžić E; Nambron R; Costelloe SJ; Martin NG; Hill NR; Frost C; Watt HC; Hindmarsh P; Björkqvist M; Warner TT
    PLoS One; 2015; 10(10):e0138848. PubMed ID: 26431314
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression.
    Pouladi MA; Xie Y; Skotte NH; Ehrnhoefer DE; Graham RK; Kim JE; Bissada N; Yang XW; Paganetti P; Friedlander RM; Leavitt BR; Hayden MR
    Hum Mol Genet; 2010 Apr; 19(8):1528-38. PubMed ID: 20097678
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Neuroendocrine disturbances in Huntington's disease.
    Saleh N; Moutereau S; Durr A; Krystkowiak P; Azulay JP; Tranchant C; Broussolle E; Morin F; Bachoud-Lévi AC; Maison P
    PLoS One; 2009; 4(3):e4962. PubMed ID: 19319184
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The endocrine profile of bromocriptine: its application in endocrine diseases.
    Lancranjan I
    J Neural Transm; 1981; 51(1-2):61-82. PubMed ID: 6455501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.